TECHNICAL MANUAL
For Veterinarians - Merial
For Veterinarians - Merial
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Pharmacokinetic and pharmacodynamic characteristics<br />
• ZACTRAN® (gamithromycin) is ≥95% bioavailable following subcutaneous (SC) injection. 4 *<br />
• ZACTRAN is rapidly and extensively distributed throughout the lungs following SC injection. 3-5 *<br />
• ZACTRAN reaches levels above MIC 90<br />
for common bacterial BRD pathogens in lung tissue<br />
within 30 minutes. 5 *<br />
• ZACTRAN remains at high concentrations above MIC 90<br />
in lung tissue and<br />
bronchoalveolar lavage (BAL) cells for 10 days. 5 *<br />
* Clinical relevance has not been determined.<br />
Clinical study results<br />
• In field trials, cattle treated with ZACTRAN showed a rapid response and significant<br />
improvement in BRD clinical signs within 24 hours after treatment. 1<br />
• In field trials, ZACTRAN provided 10-day treatment and control of BRD from a single dose. 1,2<br />
Indications 3<br />
ZACTRAN is indicated for the treatment of BRD associated with Mannheimia haemolytica,<br />
Pasteurella multocida and Histophilus somni in beef and non-lactating dairy cattle.<br />
ZACTRAN is also indicated for the control of respiratory disease in beef and non-lactating dairy cattle<br />
at high risk of developing BRD associated with M. haemolytica and P. multocida.<br />
IMPORTANT SAFETY INFORMATION: For use in cattle only. Do not treat cattle within 35 days<br />
of slaughter. Because a discard time in milk has not been established, do not use in female dairy cattle<br />
20 months of age or older, or in calves to be processed for veal. The effects of ZACTRAN on bovine<br />
reproductive performance, pregnancy and lactation have not been determined.<br />
3